Enveric Biosciences, Inc. ENVB 深 沪
等待开盘 08-19 09:30:00 美东时间
1.35
-0.130
-8.78%
华盛通- 最 高1.5999
- 今 开1.48
- 成交量 68.92万股
- 最 低 1.34
- 昨 收 1.48
- 总市值 604.24万
- 52周最高 13.6272
- 市盈率 静 --
- 换手率 15.40%
- 52周最低 1.25
- 委 比 -47.57%
- 总股本 447.59万
- 历史最高 2700000.00
- 量 比 14.37
- 振 幅 17.56%
- 历史最低 1.25
- 每 手 1
- 风险率 3.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enveric Biosciences GAAP EPS of -$0.76
Enveric Biosciences press release (ENVB): Q2 GAAP EPS of -$0.76. The company had cash-on-hand of $8.3 million as of June 30, 2026. For the quarter ended June 30, 2026, the company raised gross proceed...
08-17 16:10
Enveric Biosciences Q2 EPS $(0.76) Up From $(11.64) YoY
Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.76) per share. This is a 93.47 percent increase over losses of $(11.64) per share from the same period last year.
08-15 04:32
Enveric Biosciences将出席B. Riley证券峰会 聚焦神经精神药物开发
生物技术公司Enveric Biosciences周一宣布，将参与B． Riley证券举办的Mind， Muscle & Vision峰会。公司首席...
06-30 03:23
Enveric Biosciences Expands At-The-Market Equity Offering
Enveric Biosciences ( ($ENVB) ) just unveiled an update. On June 9, 2026, Enver...
06-10 06:51
Enveric Biosciences Releases Updated Investor Presentation Materials
An update from Enveric Biosciences ( ($ENVB) ) is now available. Enveric Biosci...
06-09 18:47
Enveric Biosciences Initiates Investigational New Drug-enabling Genotoxicity Studies Of EB-003
Studies are designed to evaluate the potential for the compound to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission
06-02 20:10
Enveric Biosciences shares are trading lower. The company announced preclinical in vitro results showing no photoreactive potential for EB‑003, further derisking its neuropsychiatric program.
Enveric Biosciences shares are trading lower. The company announced preclinical...
05-20 01:34
Enveric Biosciences Q1 EPS $(1.08) Up From $(14.64) YoY
Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(1.08) per share. This is a 92.62 percent increase over losses of $(14.64) per share from the same period last year.
05-15 20:16
